Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
2상
조기 종료
NCT06585150
| 대상 질환 | RSV Infection |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Gilead Sciences |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 150 명 |
|---|
| 중재(약물) | Obeldesivir, Obeldesivir Placebo |
|---|
| 시작일 | 2024년 10월 14일 |
|---|
| 완료일 | 2025년 5월 8일 |
|---|
| 결과 공개일 | 2026년 6월 30일 |
|---|
요약
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
Up to Day 15 · days
| Obeldesivir | 3.2 days |
|---|
| Placebo | 3.9 days |
|---|
| p-value | 0.2005 |
|---|
| Difference in median time | -0.7 |
|---|
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 13.5 percentage of participants |
|---|
| Placebo | 16.2 percentage of participants |
|---|
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 59.5 percentage of participants |
|---|
| Placebo | 57.5 percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.